echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > [Collection] PD-1/PD-L1 drugs (NMPA/FDA) approved indications

    [Collection] PD-1/PD-L1 drugs (NMPA/FDA) approved indications

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In recent years, tumor immunotherapy (Immunology Oncology Therapy, IO) has become one of the important methods for the treatment of malignant tumors
    .


    Tumor immunotherapy does not directly attack cancer cells, but fights tumors by activating the body's own immune system, which has good safety and tolerance


    PD-1/L1 antibody drugs, as a representative drug for tumor immunotherapy, have achieved great success in the treatment of malignant tumors


    Since 2014, the world’s first PD-1 inhibitor, Opdivo, has been published.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.